Cefpodoxime Limitations in Treating Enterobacter Infections

Clinical Implications and Resistance Concerns

Extended use of cephalosporins should be discouraged in settings with high ESBL-producing Enterobacteriaceae prevalence due to selective pressure resulting in emergence of resistance 1, 2
Enterobacter species are known for inducible AmpC beta-lactamase production, which can lead to treatment failure even when initial susceptibility testing suggests sensitivity 1
Cephalosporins should be limited to pathogen-directed therapy only after susceptibility testing confirms activity 1

Carbapenems remain the preferred agents for serious Enterobacter infections, particularly in hospital-acquired settings 1
Newer beta-lactam/beta-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam) have strong activity against ESBL-producing Enterobacteriaceae and should be considered for multidrug-resistant organisms 1, 2
Fluoroquinolones may be considered in select cases with documented susceptibility, though resistance rates have increased 1

Do not use cefpodoxime empirically for suspected Enterobacter infections, especially in hospital-acquired or healthcare-associated infections where resistance is more likely 1
Avoid relying on initial susceptibility testing alone for Enterobacter, as inducible resistance mechanisms can emerge during therapy 1
In settings with high ESBL prevalence, broader-spectrum agents should be selected initially rather than attempting therapy with oral cephalosporins 1